Dicerna to Present at Two Upcoming Investor Conferences

Jefferies Healthcare Conference 2014
Stifel Nicolaus Weisel Healthcare Conference 2014

WATERTOWN, Mass.--()--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., President and CEO, will present at two upcoming conferences, including the Stifel 2014 Healthcare Conference and the Jefferies 2014 Global London Healthcare Conference.

Stifel 2014 Healthcare Conference
November 18, 2014
The New York Palace Hotel, New York, NY
Presentation: 11:30 AM - 12:00 PM EST

Jefferies 2014 Global London Healthcare Conference
November 20, 2014
Waldorf Hilton, London, U.K.
Presentation: 10:00 AM - 10:40 AM GMT (5:00 AM EST)

A live webcast of the presentations can be accessed by visiting "Events & Presentations" in the Investors and Media section on the Company's website at www.dicerna.com. An archived replay of the webcasts will be available on the Company's website after the conferences.

About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.


Investor Contact:
Westwicke Partners
Yolanda Taylor, 617-366-6803
Media Contact:
Alex Van Rees, 973-442-1555 ext. 111

Dicerna Pharmaceuticals, Inc.